Drug
SM 13496
SM 13496: highest development phase Phase 3, developed by Sumitomo Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SM-13496 NCT01614912 | Phase 3 | Schizophrenia |
Latest
No recent events.
Follow SM 13496 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.